The Biochemical, Biological, and Pathological Kaleidoscope of Cell Surface Substrates Processed by Matrix Metalloproteinases

ABSTRACT Matrix metalloproteinases (MMPs) constitute a family of more than 20 endopeptidases. Identification of specific matrix and non-matrix components as MMP substrates showed that, aside from their initial role as extracellular matrix modifiers, MMPs play significant roles in highly complex processes such as the regulation of cell behavior, cell-cell communication, and tumor progression. Thanks to the comprehensive examination of the expanded MMP action radius, the initial view of proteases acting in the soluble phase has evolved into a kaleidoscope of proteolytic reactions connected to the cell surface. Important classes of cell surface molecules include adhesion molecules, mediators of apoptosis, receptors, chemokines, cytokines, growth factors, proteases, intercellular junction proteins, and structural molecules. Proteolysis of cell surface proteins by MMPs may have extremely diverse biological implications, ranging from maturation and activation, to inactivation or degradation of substrates. In this way, modification of membrane-associated proteins by MMPs is crucial for communication between cells and the extracellular milieu, and determines cell fate and the integrity of tissues. Hence, insights into the processing of cell surface proteins by MMPs and the concomitant effects on physiological processes as well as on disease onset and evolution, leads the way to innovative therapeutic approaches for cancer, as well as degenerative and inflammatory diseases.

[1]  Yi Tang,et al.  Tumor-stroma interaction: positive feedback regulation of extracellular matrix metalloproteinase inducer (EMMPRIN) expression and matrix metalloproteinase-dependent generation of soluble EMMPRIN. , 2004, Molecular cancer research : MCR.

[2]  R. Hammer,et al.  LDL receptor-related protein internalizes and degrades uPA-PAI-1 complexes and is essential for embryo implantation , 1992, Cell.

[3]  J. Arribas,et al.  The Shedding of Betaglycan Is Regulated by Pervanadate and Mediated by Membrane Type Matrix Metalloprotease-1* , 2004, Journal of Biological Chemistry.

[4]  T. Luger,et al.  Tumor-derived matrix metalloproteinase-1 targets endothelial proteinase-activated receptor 1 promoting endothelial cell activation. , 2006, Cancer research.

[5]  Hiroshi Sato,et al.  Roles of membrane‐type matrix metalloproteinase‐1 in tumor invasion and metastasis , 2005, Cancer science.

[6]  G. Opdenakker,et al.  Leukocyte gelatinase B cleavage releases encephalitogens from human myelin basic protein. , 1993, Biochemical and biophysical research communications.

[7]  岡田 伸太郎,et al.  Matrix Metalloproteinase-9 , 1998, Definitions.

[8]  S. Ménard,et al.  Formation of the 67‐kDa laminin receptor by acylation of the precursor , 1998, Journal of cellular biochemistry.

[9]  A. Gearing,et al.  Design and therapeutic application of matrix metalloproteinase inhibitors. , 1999, Chemical reviews.

[10]  L. Liotta,et al.  Galectin-3 is a novel substrate for human matrix metalloproteinases-2 and -9. , 1994, Biochemistry.

[11]  Li Yan,et al.  Roles of the multifunctional glycoprotein, emmprin (basigin; CD147), in tumour progression , 2005, Thrombosis and Haemostasis.

[12]  Alex Y Strongin,et al.  An Alternative Processing of Integrin αv Subunit in Tumor Cells by Membrane Type-1 Matrix Metalloproteinase* , 2002, The Journal of Biological Chemistry.

[13]  L. Blavier,et al.  Considering the critical interface between tumor cells and stromal cells in the search for targets for anticancer therapy. , 2005, Cancer cell.

[14]  D. Green,et al.  Metalloproteinase shedding of Fas ligand regulates beta-amyloid neurotoxicity. , 2002, Current biology : CB.

[15]  E. Mekada,et al.  Heparin-binding EGF-like growth factor: a juxtacrine growth factor. , 2000, Cytokine & growth factor reviews.

[16]  B. Fingleton,et al.  Matrilysin (matrix metalloproteinase-7) selects for apoptosis-resistant mammary cells in vivo. , 2002, Cancer research.

[17]  P. Altevogt,et al.  Metalloproteinase-mediated release of the ectodomain of L1 adhesion molecule. , 1999, Journal of cell science.

[18]  M. Umeda,et al.  GelatinaseA and APP , 1994, Nature.

[19]  C. S. St. Hill,et al.  ADAM‐17‐independent shedding of L‐selectin , 2003, Journal of leukocyte biology.

[20]  A. Strongin,et al.  Processing of integrin alpha(v) subunit by membrane type 1 matrix metalloproteinase stimulates migration of breast carcinoma cells on vitronectin and enhances tyrosine phosphorylation of focal adhesion kinase. , 2002, The Journal of biological chemistry.

[21]  B. Fingleton,et al.  Matrix metalloproteinase-7-dependent release of tumor necrosis factor-alpha in a model of herniated disc resorption. , 2000, The Journal of clinical investigation.

[22]  M. Torrisi,et al.  Phospholipases C and A2 control lysosome-mediated IL-1 beta secretion: Implications for inflammatory processes. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[23]  Gillian Murphy,et al.  Structure and function of matrix metalloproteinases and TIMPs. , 2006, Cardiovascular research.

[24]  T. Isobe,et al.  Membrane Type 1 Matrix Metalloproteinase (MT1-MMP/MMP-14) Cleaves and Releases a 22-kDa Extracellular Matrix Metalloproteinase Inducer (EMMPRIN) Fragment from Tumor Cells* , 2006, Journal of Biological Chemistry.

[25]  Y. Dai,et al.  Characterization of the soluble form of the low density lipoprotein receptor-related protein (LRP). , 1999, Experimental cell research.

[26]  C. Blobel,et al.  Tumor necrosis factor-alpha converting enzyme/ADAM 17 mediates MUC1 shedding. , 2003, The Journal of biological chemistry.

[27]  Y. Yarden,et al.  Oncogenic growth factor receptors: implications for signal transduction therapy. , 2004, Seminars in cancer biology.

[28]  I. Nishino,et al.  Proteolysis of β-dystroglycan in muscular diseases , 2005, Neuromuscular Disorders.

[29]  William C. Parks,et al.  Matrilysin Shedding of Syndecan-1 Regulates Chemokine Mobilization and Transepithelial Efflux of Neutrophils in Acute Lung Injury , 2002, Cell.

[30]  H. Saya,et al.  Proteolytic release of CD44 intracellular domain and its role in the CD44 signaling pathway , 2001, The Journal of cell biology.

[31]  P. Altevogt,et al.  Cleavage of L1 in Exosomes and Apoptotic Membrane Vesicles Released from Ovarian Carcinoma Cells , 2005, Clinical Cancer Research.

[32]  G. Davis,et al.  Ischemia-induced cleavage of cadherins in NRK cells: evidence for a role of metalloproteinases. , 2005, American journal of physiology. Renal physiology.

[33]  S. Belmadani,et al.  Involvement of Metalloproteinases 2/9 in Epidermal Growth Factor Receptor Transactivation in Pressure-Induced Myogenic Tone in Mouse Mesenteric Resistance Arteries , 2004, Circulation.

[34]  R. Caldwell,et al.  TGF-beta increases retinal endothelial cell permeability by increasing MMP-9: possible role of glial cells in endothelial barrier function. , 2001, Investigative ophthalmology & visual science.

[35]  A. Steinle,et al.  Proteolytic release of soluble UL16-binding protein 2 from tumor cells. , 2006, Cancer research.

[36]  D. Gomez,et al.  Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. , 1997, European journal of cell biology.

[37]  B. C. Patterson,et al.  Angiostatin-converting Enzyme Activities of Human Matrilysin (MMP-7) and Gelatinase B/Type IV Collagenase (MMP-9)* , 1997, The Journal of Biological Chemistry.

[38]  E. Milgrom,et al.  Shedding of Human Thyrotropin Receptor Ectodomain , 1996, The Journal of Biological Chemistry.

[39]  E. Bröcker,et al.  Granulocyte‐derived elastase and gelatinase B are required for dermal–epidermal separation induced by autoantibodies from patients with epidermolysis bullosa acquisita and bullous pemphigoid , 2004, The Journal of pathology.

[40]  Hiroshi Ohno,et al.  Cytoplasmic tail–dependent internalization of membrane-type 1 matrix metalloproteinase is important for its invasion-promoting activity , 2001, The Journal of cell biology.

[41]  William C. Parks,et al.  Matrix metalloproteinases as modulators of inflammation and innate immunity , 2004, Nature Reviews Immunology.

[42]  K. Brew,et al.  Tissue inhibitors of metalloproteinases: evolution, structure and function. , 2000, Biochimica et biophysica acta.

[43]  G. Opdenakker,et al.  Cytokine-regulated proteases in autoimmune diseases. , 1994, Immunology today.

[44]  M. Feldmann,et al.  Paradoxical effects of a synthetic metalloproteinase inhibitor that blocks both p55 and p75 TNF receptor shedding and TNF alpha processing in RA synovial membrane cell cultures. , 1996, The Journal of clinical investigation.

[45]  I. Mikhailenko,et al.  Beyond endocytosis: LRP function in cell migration, proliferation and vascular permeability , 2005, Journal of thrombosis and haemostasis : JTH.

[46]  A. Hopkins,et al.  ICAM-1: targeted docking for exogenous as well as endogenous ligands. , 2004, Advanced drug delivery reviews.

[47]  N. Mitsiades,et al.  The role of Fas and FasL as mediators of anticancer chemotherapy. , 2001, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[48]  N. Hooper,et al.  Membrane protein secretases. , 1997, The Biochemical journal.

[49]  D. Rifkin,et al.  Cellular glycosylphosphatidylinositol‐specific phospholipase D regulates urokinase receptor shedding and cell surface expression , 1999, Journal of cellular physiology.

[50]  Motoharu Seiki,et al.  MT1‐MMP: A potent modifier of pericellular microenvironment , 2006, Journal of cellular physiology.

[51]  S. Itohara,et al.  Unaltered Secretion of β-Amyloid Precursor Protein in Gelatinase A (Matrix Metalloproteinase 2)-deficient Mice* , 1997, The Journal of Biological Chemistry.

[52]  A. Kozik,et al.  Effect of oxidation of β‐amyloid precursor protein on its β‐secretase cleavage. A model study with synthetic peptides and candidate β‐secretases , 2009 .

[53]  D. Green,et al.  Metalloproteinase Shedding of Fas Ligand Regulates β-Amyloid Neurotoxicity , 2002, Current Biology.

[54]  T. Yoshizaki,et al.  Cleavage of Syndecan-1 by Membrane Type Matrix Metalloproteinase-1 Stimulates Cell Migration* , 2003, Journal of Biological Chemistry.

[55]  R. Dwek,et al.  The Hemopexin and O-Glycosylated Domains Tune Gelatinase B/MMP-9 Bioavailability via Inhibition and Binding to Cargo Receptors* , 2006, Journal of Biological Chemistry.

[56]  H. Mori,et al.  Membrane-Type 1 Matrix Metalloproteinase Cleaves Cd44 and Promotes Cell Migration , 2001, The Journal of cell biology.

[57]  Gillian Murphy,et al.  Membrane type I-matrix metalloproteinase (MT1-MMP) is internalised by two different pathways and is recycled to the cell surface , 2003, Journal of Cell Science.

[58]  W. Birchmeier,et al.  Cadherin expression in carcinomas: role in the formation of cell junctions and the prevention of invasiveness. , 1994, Biochimica et biophysica acta.

[59]  D. Górecki,et al.  Aberrant expression, processing and degradation of dystroglycan in squamous cell carcinomas. , 2004, European journal of cancer.

[60]  C. Blobel,et al.  Tumor Necrosis Factor-α Converting Enzyme/ADAM 17 Mediates MUC1 Shedding* , 2003, The Journal of Biological Chemistry.

[61]  M. Greenberg,et al.  β-Amyloid Induces Neuronal Apoptosis Via a Mechanism that Involves the c-Jun N-Terminal Kinase Pathway and the Induction of Fas Ligand , 2001, The Journal of Neuroscience.

[62]  L. Kotra,et al.  Complex Pattern of Membrane Type 1 Matrix Metalloproteinase Shedding , 2002, The Journal of Biological Chemistry.

[63]  G. Murphy,et al.  Metalloproteinase-mediated Regulation of L-selectin Levels on Leucocytes (*) , 1996, The Journal of Biological Chemistry.

[64]  Yunbo Shi,et al.  The matrix metalloproteinase stromelysin-3 cleaves laminin receptor at two distinct sites between the transmembrane domain and laminin binding sequence within the extracellular domain , 2005, Cell Research.

[65]  A. Reichenbach,et al.  Role of Muller cells in retinal degenerations. , 2001, Frontiers in bioscience : a journal and virtual library.

[66]  Carlos Fernandez-Patron,et al.  Agonist-Induced Activation of Matrix Metalloproteinase-7 Promotes Vasoconstriction Through the Epidermal Growth Factor–Receptor Pathway , 2004, Circulation research.

[67]  B. Fingleton,et al.  Matrix Metalloproteinase Inhibitors and Cancer—Trials and Tribulations , 2002, Science.

[68]  M. Cullen,et al.  Matrix Metalloproteinases in Dog Brains Exhibiting Alzheimer‐Like Characteristics , 1997, Journal of neurochemistry.

[69]  Z. Werb,et al.  Matrix Metalloproteinase Stromelysin-1 Triggers a Cascade of Molecular Alterations That Leads to Stable Epithelial-to-Mesenchymal Conversion and a Premalignant Phenotype in Mammary Epithelial Cells , 1997, The Journal of cell biology.

[70]  H. Matsuno,et al.  Potential withdrawal of rheumatoid synovium by the induction of apoptosis using a novel in vivo model of rheumatoid arthritis. , 1998, Arthritis and rheumatism.

[71]  L. Taubner,et al.  Tumor shedding of laminin binding protein modulates angiostatin production in vitro and interferes with plasmin‐derived inhibition of angiogenesis in aortic ring cultures , 2006, International journal of cancer.

[72]  W. Sakr,et al.  Cleavage at the stem region releases an active ectodomain of the membrane type 1 matrix metalloproteinase. , 2005, The Biochemical journal.

[73]  W. Parks,et al.  Matrilysin (matrix metalloproteinase-7) mediates E-cadherin ectodomain shedding in injured lung epithelium. , 2003, The American journal of pathology.

[74]  Jeffrey W. Smith,et al.  Functional activation of integrin αvβ3 in tumor cells expressing membrane‐type 1 matrix metalloproteinase , 2000 .

[75]  W. McGuire,et al.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.

[76]  I. Weissman,et al.  A cell-surface molecule involved in organ-specific homing of lymphocytes , 1983, Nature.

[77]  A. Ullrich,et al.  EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF , 1999, Nature.

[78]  A. H. Drummond,et al.  Processing of tumour necrosis factor-alpha precursor by metalloproteinases. , 1994, Nature.

[79]  J. Foidart,et al.  Upregulation of MMPs by soluble E‐cadherin in human lung tumor cells , 2003, International journal of cancer.

[80]  S. Moe,et al.  Opposing Effects of Transmembrane and Soluble FAS Ligand Expression on Inflammation and Tumor Cell Survival , 2000, The Journal of experimental medicine.

[81]  K. Guan,et al.  Class IV Semaphorins Promote Angiogenesis by Stimulating Rho-Initiated Pathways through Plexin-B , 2004, Cancer Research.

[82]  Y. Itoh,et al.  MT1-MMP: an enzyme with multidimensional regulation. , 2004, Trends in biochemical sciences.

[83]  E. Sturrock,et al.  Soluble LDL-R are formed by cell surface cleavage in response to phorbol esters. , 2004, European journal of biochemistry.

[84]  M. Ball,et al.  Proteolysis of Aβ Peptide from Alzheimer Disease Brain by Gelatinase A , 1994 .

[85]  Michael A. Hollingsworth,et al.  Mucins in cancer: protection and control of the cell surface , 2004, Nature Reviews Cancer.

[86]  J. Marvaldi,et al.  Role of Endoproteolytic Processing in the Adhesive and Signaling Functions of αvβ5 Integrin* , 2000, The Journal of Biological Chemistry.

[87]  S. Gordon,et al.  A Functional Soluble Form of the Murine Mannose Receptor Is Produced by Macrophages in Vitro and Is Present in Mouse Serum* , 1998, The Journal of Biological Chemistry.

[88]  Brian Chung,et al.  Linking Receptor-mediated Endocytosis and Cell Signaling , 2004, Journal of Biological Chemistry.

[89]  G. Murphy,et al.  Tissue Inhibitor of Metalloproteinases-3 Inhibits Shedding of L-selectin from Leukocytes* , 1999, The Journal of Biological Chemistry.

[90]  M. Gerhart,et al.  Protection against a lethal dose of endotoxin by an inhibitor of tumour necrosis factor processing , 1994, Nature.

[91]  M. Lisanti,et al.  Src tyrosine kinases, Galpha subunits, and H-Ras share a common membrane-anchored scaffolding protein, caveolin. Caveolin binding negatively regulates the auto-activation of Src tyrosine kinases. , 1996, The Journal of biological chemistry.

[92]  J. Woessner,et al.  Heparan Sulfate Proteoglycans as Extracellular Docking Molecules for Matrilysin (Matrix Metalloproteinase 7)* , 2000, The Journal of Biological Chemistry.

[93]  I. Stamenkovic,et al.  Perturbation of hyaluronan interactions by soluble CD44 inhibits growth of murine mammary carcinoma cells in ascites. , 2000, The American journal of pathology.

[94]  S. Ménard,et al.  Peptide G, Containing the Binding Site of the 67-kDa Laminin Receptor, Increases and Stabilizes Laminin Binding to Cancer Cells* , 1996, The Journal of Biological Chemistry.

[95]  M. Ploug,et al.  Structure-function relationships in the receptor for urokinase-type plasminogen activator. Comparison to other members of the Ly-6 family and snake venom alpha-neurotoxins. , 1994, FEBS letters.

[96]  A. Strongin,et al.  Matrix-dependent Proteolysis of Surface Transglutaminase by Membrane-type Metalloproteinase Regulates Cancer Cell Adhesion and Locomotion* , 2001, The Journal of Biological Chemistry.

[97]  C. López-Otín,et al.  Matrix metalloproteinases in cancer: from new functions to improved inhibition strategies. , 2004, The International journal of developmental biology.

[98]  H. Rammensee,et al.  Cutting Edge: Down-Regulation of MICA on Human Tumors by Proteolytic Shedding , 2002, The Journal of Immunology.

[99]  R. Fridman,et al.  Processing, shedding, and endocytosis of membrane type 1‐matrix metalloproteinase (MT1‐MMP) , 2004, Journal of cellular physiology.

[100]  J. Tonn,et al.  Production of MMPs in Human Cerebral Endothelial Cells and Their Role in Shedding Adhesion Molecules , 2001, Journal of neuropathology and experimental neurology.

[101]  B. Toole,et al.  Hyaluronan: from extracellular glue to pericellular cue , 2004, Nature Reviews Cancer.

[102]  R. Burghardt,et al.  Ischemia-induced cleavage of cadherins in NRK cells requires MT1-MMP (MMP-14). , 2006, American journal of physiology. Renal physiology.

[103]  D. Hadjipavlou-Litina,et al.  Matrix metalloproteinase inhibitors: a review on pharmacophore mapping and (Q)SARs results. , 2005, Current medicinal chemistry.

[104]  T. Sano,et al.  [Diabetic retinopathy]. , 2001, Nihon rinsho. Japanese journal of clinical medicine.

[105]  M. Furman,et al.  Release of soluble CD40L from platelets is regulated by glycoprotein IIb/IIIa and actin polymerization. , 2004, Journal of the American College of Cardiology.

[106]  Membrane type-1 matrix metalloproteinase (MT1-MMP) processing of pro-alphav integrin regulates cross-talk between alphavbeta3 and alpha2beta1 integrins in breast carcinoma cells. , 2003, Experimental cell research.

[107]  Ronit Vogt Sionov,et al.  CD44: structure, function, and association with the malignant process. , 1997, Advances in cancer research.

[108]  C. Masters,et al.  Degradation of the Alzheimer Disease Amyloid β-Peptide by Metal-dependent Up-regulation of Metalloprotease Activity* , 2006, Journal of Biological Chemistry.

[109]  Nicole Nelson,et al.  A metalloproteinase disintegrin that releases tumour-necrosis factor-α from cells , 1997, Nature.

[110]  S. Chandler,et al.  Matrix metalloproteinases degrade myelin basic protein , 1995, Neuroscience Letters.

[111]  C. Powers,et al.  Fibroblast growth factors, their receptors and signaling. , 2000, Endocrine-related cancer.

[112]  M. Fini,et al.  Effects of Matrix Metalloproteinase-9 Gene Knock-Out on the Proteolysis of Blood–Brain Barrier and White Matter Components after Cerebral Ischemia , 2001, The Journal of Neuroscience.

[113]  M. Ploug,et al.  Structure—function relationships in the receptor for urokinase‐type plasminogen activator Comparison to other members of the Ly‐6 family and snake venom α‐neurotoxins , 1994 .

[114]  R. Sciot,et al.  Resistance of young gelatinase B-deficient mice to experimental autoimmune encephalomyelitis and necrotizing tail lesions. , 1999, The Journal of clinical investigation.

[115]  R. Dwek,et al.  Matrix remodelling enzymes, the protease cascade and glycosylation. , 2001, Biochimica et biophysica acta.

[116]  N. Bunnett,et al.  Protease-activated receptors: contribution to physiology and disease. , 2004, Physiological reviews.

[117]  A. Bensussan,et al.  A Soluble Form of the MHC Class I-Specific CD160 Receptor Is Released from Human Activated NK Lymphocytes and Inhibits Cell-Mediated Cytotoxicity1 , 2007, The Journal of Immunology.

[118]  B. Fingleton,et al.  The metalloproteinase matrilysin proteolytically generates active soluble Fas ligand and potentiates epithelial cell apoptosis , 1999, Current Biology.

[119]  P. Dempsey,et al.  Tyrosine Phosphorylation and Proteolysis , 1998, The Journal of Biological Chemistry.

[120]  D. Carey,et al.  Matrix metalloproteinase‐dependent shedding of syndecan‐3, a transmembrane heparan sulfate proteoglycan, in Schwann cells , 2003, Journal of neuroscience research.

[121]  J. Mitchison Cell Biology , 1964, Nature.

[122]  Z. Werb,et al.  New functions for the matrix metalloproteinases in cancer progression , 2002, Nature Reviews Cancer.

[123]  S. Roman-Roman,et al.  Identification of the cleavage site involved in production of plasma soluble Fc gamma receptor type III (CD16) , 1998, European journal of immunology.

[124]  R. Coffey,et al.  Cell Surface Ectodomain Cleavage of Human Amphiregulin Precursor Is Sensitive to a Metalloprotease Inhibitor , 1998, The Journal of Biological Chemistry.

[125]  X. Puente,et al.  Membrane Type 4 Matrix Metalloproteinase (MMP17) Has Tumor Necrosis Factor-α Convertase Activity but Does Not Activate Pro-MMP2* , 2000, The Journal of Biological Chemistry.

[126]  R. Caldwell,et al.  TGF-β increases retinal endothelial cell permeability by increasing MMP-9 : Possible role of glial cells in endothelial barrier function , 2001 .

[127]  S. Rafii,et al.  Recruitment of Stem and Progenitor Cells from the Bone Marrow Niche Requires MMP-9 Mediated Release of Kit-Ligand , 2002, Cell.

[128]  A. Churg,et al.  Macrophage metalloelastase mediates acute cigarette smoke-induced inflammation via tumor necrosis factor-alpha release. , 2003, American journal of respiratory and critical care medicine.

[129]  Alex Y Strongin,et al.  Cell-surface-associated tissue transglutaminase is a target of MMP-2 proteolysis. , 2004, Biochemistry.

[130]  A. Ullrich,et al.  The EGF receptor as central transducer of heterologous signalling systems. , 1999, Trends in pharmacological sciences.

[131]  P. Thompson,et al.  Modulatory effects of sCD14 and LBP on LPS-host cell interactions , 2005, Journal of endotoxin research.

[132]  M. Hirashima,et al.  Regulation of galectin-9 expression and release in Jurkat T cell line cells. , 2002, Glycobiology.

[133]  S. Coughlin,et al.  Thrombin signalling and protease-activated receptors , 2000, Nature.

[134]  D. Sheppard,et al.  Heparin-binding epidermal growth factor cleavage mediates zinc-induced epidermal growth factor receptor phosphorylation. , 2004, American journal of respiratory cell and molecular biology.

[135]  A. Strongin,et al.  Functional activation of integrin alpha V beta 3 in tumor cells expressing membrane-type 1 matrix metalloproteinase. , 2000, International journal of cancer.

[136]  P. Ongusaha,et al.  HB-EGF Is a Potent Inducer of Tumor Growth and Angiogenesis , 2004, Cancer Research.

[137]  D. Gingras,et al.  Localization of membrane-type 1 matrix metalloproteinase in caveolae membrane domains. , 2001, The Biochemical journal.

[138]  M. Seiki,et al.  Sequence-specific silencing of MT1-MMP expression suppresses tumor cell migration and invasion: importance of MT1-MMP as a therapeutic target for invasive tumors , 2003, Oncogene.

[139]  T. van der Poll,et al.  The Metalloproteinase Inhibitor GI5402 Inhibits Endotoxin-Induced Soluble CD27 and CD16 Release in Healthy Humans , 2000, Infection and Immunity.

[140]  R. Coffey,et al.  Apical Enrichment of Human EGF Precursor in Madin-Darby Canine Kidney Cells Involves Preferential Basolateral Ectodomain Cleavage Sensitive to a Metalloprotease Inhibitor , 1997, The Journal of cell biology.

[141]  M. Oda,et al.  Analysis of the ternary complex formation of human urokinase with the separated two domains of its receptor. , 1998, European journal of biochemistry.

[142]  L. Matrisian,et al.  Matrix metalloproteinases: they're not just for matrix anymore! , 2001, Current opinion in cell biology.

[143]  L. Pegg,et al.  ADAMTS-4 (aggrecanase-1): N-terminal activation mechanisms. , 2005, Archives of biochemistry and biophysics.

[144]  Marcel Mettlen,et al.  Regulation of matrix metalloproteinase (MMP) activity by the low-density lipoprotein receptor-related protein (LRP). A new function for an "old friend". , 2005, Biochimie.

[145]  R. Elble,et al.  The Breast Cancer β4 Integrin and Endothelial Human CLCA2 Mediate Lung Metastasis* , 2001, The Journal of Biological Chemistry.

[146]  C. Overall,et al.  Matrix Metalloproteinase Activity Inactivates the CXC Chemokine Stromal Cell-derived Factor-1* , 2001, The Journal of Biological Chemistry.

[147]  R. Black,et al.  A metalloprotease inhibitor blocks shedding of the IL-6 receptor and the p60 TNF receptor. , 1995, Journal of immunology.

[148]  K. Miyazaki,et al.  Novel processing of beta-amyloid precursor protein catalyzed by membrane type 1 matrix metalloproteinase releases a fragment lacking the inhibitor domain against gelatinase A. , 2003, Biochemistry.

[149]  M. De Ley,et al.  Homogeneous interferon-inducing 22K factor is related to endogenous pyrogen and interleukin-1 , 1985, Nature.

[150]  Gillian Murphy,et al.  Metalloproteinase inhibitors: biological actions and therapeutic opportunities , 2002, Journal of Cell Science.

[151]  R. Mayer,et al.  Hydroxamate-based inhibitors of low affinity IgE receptor (CD23) processing. , 1998, Bioorganic & medicinal chemistry letters.

[152]  G. Opdenakker,et al.  Matrix Metalloproteinase-9 Facilitates Remyelination in Part by Processing the Inhibitory NG2 Proteoglycan , 2003, The Journal of Neuroscience.

[153]  D. Strickland,et al.  Diverse roles for the LDL receptor family , 2002, Trends in Endocrinology & Metabolism.

[154]  Hiroyuki Arai,et al.  Matrix metalloproteinase (MMP) system in brain: identification and characterization of brain‐specific MMP highly expressed in cerebellum , 2001, The European journal of neuroscience.

[155]  S. Roman-Roman,et al.  A metalloproteinase inhibitor blocks the shedding of soluble cytokine receptors and processing of transmembrane cytokine precursors in human monocytic cells. , 1997, Cytokine.

[156]  K. Miyazaki,et al.  Identification of a Region of β-Amyloid Precursor Protein Essential for Its Gelatinase A Inhibitory Activity* , 2003, The Journal of Biological Chemistry.

[157]  A. Kahn,et al.  The Cell Surface , 1974, Advances in Experimental Medicine and Biology.

[158]  M. Rouis Matrix metalloproteinases: a potential therapeutic target in atherosclerosis. , 2005, Current drug targets. Cardiovascular & haematological disorders.

[159]  J. Gutkind,et al.  Semaphorin 4D provides a link between axon guidance processes and tumor-induced angiogenesis. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[160]  H. Birkedal‐Hansen,et al.  The cysteine switch: a principle of regulation of metalloproteinase activity with potential applicability to the entire matrix metalloproteinase gene family. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[161]  T. Sumida,et al.  Induction of apoptosis in the rheumatoid synovium by Fas ligand gene transfer , 1998, Gene Therapy.

[162]  Y. Ma,et al.  Matrix metalloproteinase 2 releases active soluble ectodomain of fibroblast growth factor receptor 1. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[163]  O. Huber,et al.  Cleavage and Shedding of E-cadherin after Induction of Apoptosis* , 2001, The Journal of Biological Chemistry.

[164]  J. Baselga,et al.  Metalloprotease-dependent protransforming growth factor-alpha ectodomain shedding in the absence of tumor necrosis factor-alpha-converting enzyme. , 2001, The Journal of biological chemistry.

[165]  R. Kemler,et al.  Control over Wnt target gene expression , 2000 .

[166]  K. Irie,et al.  Ectodomain shedding of nectin-1alpha by SF/HGF and TPA in MDCK cells. , 2002, Biochemical and biophysical research communications.

[167]  Pauline M. Rudd,et al.  Biochemistry and Molecular Biology of Gelatinase B or Matrix Metalloproteinase-9 (MMP-9) , 2002, Critical reviews in biochemistry and molecular biology.

[168]  Y. Iwakura,et al.  IL-1 is required for tumor invasiveness and angiogenesis , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[169]  B. Sheu,et al.  A novel role of metalloproteinase in cancer-mediated immunosuppression. , 2001, Cancer research.

[170]  B. H. Shah,et al.  GPCR-mediated transactivation of RTKs in the CNS: mechanisms and consequences , 2004, Trends in Neurosciences.

[171]  Gillian Murphy,et al.  Shedding of Syndecan-1 and -4 Ectodomains Is Regulated by Multiple Signaling Pathways and Mediated by a Timp-3–Sensitive Metalloproteinase , 2000, The Journal of cell biology.

[172]  Michael Koval Claudins—Key Pieces in the Tight Junction Puzzle , 2006, Cell communication & adhesion.

[173]  T. Hoang‐Xuan,et al.  EMMPRIN/CD147, an MMP modulator in cancer, development and tissue repair. , 2005, Biochimie.

[174]  C. Blobel,et al.  Remarkable roles of proteolysis on and beyond the cell surface. , 2000, Current opinion in cell biology.

[175]  T. Morio,et al.  Characterization of soluble CD40 ligand released from human activated platelets. , 2001, Journal of medical and dental sciences.

[176]  T. Major,et al.  Extracellular Matrix Metalloproteinase Inducer (EMMPRIN) Is Induced Upon Monocyte Differentiation and Is Expressed in Human Atheroma , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[177]  P. Altevogt,et al.  Ectodomain shedding of L1 adhesion molecule promotes cell migration by autocrine binding to integrins , 2001, The Journal of cell biology.

[178]  M. Gassmann,et al.  Viable c-Kit(W/W) mutants reveal pivotal role for c-kit in the maintenance of lymphopoiesis. , 2002, Immunity.

[179]  M. Mareel,et al.  Release of an invasion promoter E-cadherin fragment by matrilysin and stromelysin-1. , 2001, Journal of cell science.

[180]  Christopher M. Overall,et al.  Degradomics: Systems biology of the protease web. Pleiotropic roles of MMPs in cancer , 2006, Cancer and Metastasis Reviews.

[181]  K. Matsumura,et al.  Processing of beta-dystroglycan by matrix metalloproteinase disrupts the link between the extracellular matrix and cell membrane via the dystroglycan complex. , 2001, Human molecular genetics.

[182]  E. Milgrom,et al.  Cleavage and shedding of the TSH receptor. , 1997, European journal of endocrinology.

[183]  O. Janssen,et al.  Slowly getting a clue on CD95 ligand biology. , 2003, Biochemical pharmacology.

[184]  M. Ryan,et al.  Occludin: structure, function and regulation. , 2005, Advanced drug delivery reviews.

[185]  D. Holtzman,et al.  Matrix Metalloproteinases Expressed by Astrocytes Mediate Extracellular Amyloid-β Peptide Catabolism , 2006, The Journal of Neuroscience.

[186]  G. Gorodeski Estrogen decrease in tight junctional resistance involves matrix-metalloproteinase-7-mediated remodeling of occludin. , 2007, Endocrinology.

[187]  B. Castner,et al.  A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. , 1997, Nature.

[188]  Hiroshi Sato,et al.  Identification of the Second Membrane-type Matrix Metalloproteinase (MT-MMP-2) Gene from a Human Placenta cDNA Library , 1995, The Journal of Biological Chemistry.

[189]  E. Appella,et al.  A urokinase‐sensitive region of the human urokinase receptor is responsible for its chemotactic activity , 1997, The EMBO journal.

[190]  G. Moţa,et al.  Interaction of Human Immunoglobulin G with CD16 on Natural Killer Cells: Ligand Clearance, FcγRIIIA Turnover and Effects of Metalloproteinases on FcγRIIIA‐Mediated Binding, Signal Transduction and Killing ‡ , 2004, Scandinavian journal of immunology.

[191]  Martin Braddock,et al.  Targeting IL-1 in inflammatory disease: new opportunities for therapeutic intervention , 2004, Nature Reviews Drug Discovery.

[192]  K. Irie,et al.  Ectodomain shedding of nectin-1α by SF/HGF and TPA in MDCK cells , 2002 .

[193]  K. Yudoh,et al.  Stromelysin-1 (MMP-3) in synovial fluid of patients with rheumatoid arthritis has potential to cleave membrane bound Fas ligand. , 2001, The Journal of rheumatology.

[194]  J. Pelley,et al.  Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) and Inflammatory Stimuli Up-Regulate Secretion of the Soluble GM-CSF Receptor in Human Monocytes: Evidence for Ectodomain Shedding of the Cell Surface GM-CSF Receptor α Subunit1 , 2002, The Journal of Immunology.

[195]  R. Bast,et al.  Regulation of tumour necrosis factor-α processing by a metalloproteinase inhibitor , 1994, Nature.

[196]  Bahereh The conversion , 1983, Craft Brew.

[197]  Y. Kadono,et al.  Negative Regulation of Osteoclastogenesis by Ectodomain Shedding of Receptor Activator of NF-κB Ligand* , 2006, Journal of Biological Chemistry.

[198]  M. Ball,et al.  Proteolysis of A beta peptide from Alzheimer disease brain by gelatinase A. , 1994, Biochemical and biophysical research communications.

[199]  M. Cuzner,et al.  Plasminogen activators and matrix metalloproteases, mediators of extracellular proteolysis in inflammatory demyelination of the central nervous system , 1999, Journal of Neuroimmunology.

[200]  H. Yoshisue,et al.  Effect of MMP/ADAM Inhibitors on Goblet Cell Hyperplasia in Cultured Human Bronchial Epithelial Cells , 2004, Bioscience, biotechnology, and biochemistry.

[201]  Miki Hasegawa,et al.  A metalloproteinase inhibitor domain in Alzheimer amyloid protein precursor , 1993, Nature.

[202]  Norman Relkin,et al.  Increased plasma levels of matrix metalloproteinase-9 in patients with Alzheimer’s disease , 2003, Neurochemistry International.

[203]  S. Higashiyama Metalloproteinase-mediated shedding of heparin-binding EGF-like growth factor and its pathophysiological roles. , 2004, Protein and peptide letters.

[204]  Roy S Herbst,et al.  Review of epidermal growth factor receptor biology. , 2004, International journal of radiation oncology, biology, physics.

[205]  B. H. Shah,et al.  Matrix metalloproteinase-dependent EGF receptor activation in hypertension and left ventricular hypertrophy , 2004, Trends in Endocrinology & Metabolism.

[206]  M. Klagsbrun,et al.  Matrix Metalloproteinase-3 Releases Active Heparin-binding EGF-like Growth Factor by Cleavage at a Specific Juxtamembrane Site* , 1997, The Journal of Biological Chemistry.

[207]  R. Visse,et al.  This Review Is Part of a Thematic Series on Matrix Metalloproteinases, Which Includes the following Articles: Matrix Metalloproteinase Inhibition after Myocardial Infarction: a New Approach to Prevent Heart Failure? Matrix Metalloproteinases in Vascular Remodeling and Atherogenesis: the Good, the Ba , 2022 .

[208]  J. Villeval,et al.  Platelet activation induces metalloproteinase-dependent GP VI cleavage to down-regulate platelet reactivity to collagen. , 2005, Blood.

[209]  I. Macdonald,et al.  Metastasis: Dissemination and growth of cancer cells in metastatic sites , 2002, Nature Reviews Cancer.

[210]  A. Cress,et al.  Integrin clipping: A novel adhesion switch? , 2004, Journal of cellular biochemistry.

[211]  Y. Sasaguri,et al.  Degradation of Interleukin 1β by Matrix Metalloproteinases* , 1996, The Journal of Biological Chemistry.

[212]  J. Sandy,et al.  Activation of the Proteolytic Activity of ADAMTS4 (Aggrecanase-1) by C-terminal Truncation* , 2002, The Journal of Biological Chemistry.

[213]  Joseph D. Buxbaum,et al.  Evidence That Tumor Necrosis Factor α Converting Enzyme Is Involved in Regulated α-Secretase Cleavage of the Alzheimer Amyloid Protein Precursor* , 1998, The Journal of Biological Chemistry.

[214]  M. Fini,et al.  Matrix metalloproteinase-9 knockout confers resistance to corneal epithelial barrier disruption in experimental dry eye. , 2005, The American journal of pathology.

[215]  J K Frederiksen,et al.  Fas preassociation required for apoptosis signaling and dominant inhibition by pathogenic mutations. , 2000, Science.

[216]  M. Wewers IL-1β: An endosomal exit , 2004 .

[217]  T. Petrucci,et al.  Synaptic remodeling induced by axotomy of superior cervical ganglion neurons: Involvement of metalloproteinase-2 , 2006, Journal of Physiology-Paris.

[218]  S. Shumack,et al.  Epidemiology and pathogenesis of scleroderma , 2003, The Australasian journal of dermatology.

[219]  Munirah Ahmad,et al.  Cleavage of amyloid-beta precursor protein (APP) by membrane-type matrix metalloproteinases. , 2006, Journal of biochemistry.

[220]  K. Tanabe,et al.  The role of Fas ligand and transforming growth factor β in tumor progression , 2004 .

[221]  S. Yamasaki,et al.  Protein expression and functional difference of membrane-bound and soluble receptor activator of NF-kappaB ligand: modulation of the expression by osteotropic factors and cytokines. , 2000, Biochemical and biophysical research communications.

[222]  K. Misono,et al.  Proteolytic cleavage of atrial natriuretic factor receptor in bovine adrenal membranes by endogenous metalloendopeptidase. Effects on guanylate cyclase activity and ligand-binding specificity. , 1992, European journal of biochemistry.

[223]  E. Levin,et al.  Proximal Events in Signaling by Plasma Membrane Estrogen Receptors* , 2003, The Journal of Biological Chemistry.

[224]  M. Polette,et al.  Respective contribution of neutrophil elastase and matrix metalloproteinase 9 in the degradation of BP180 (type XVII collagen) in human bullous pemphigoid. , 2001, The Journal of investigative dermatology.

[225]  B. Fingleton,et al.  Matrix metalloproteinases: biologic activity and clinical implications. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[226]  F. Chen,et al.  The Differentiation-dependent Desmosomal Cadherin Desmoglein 1 Is a Novel Caspase-3 Target That Regulates Apoptosis in Keratinocytes* , 2006, Journal of Biological Chemistry.

[227]  P. Gottschall,et al.  Increased Production of Matrix Metalloproteinases in Enriched Astrocyte and Mixed Hippocampal Cultures Treated with β‐Amyloid Peptides , 1996 .

[228]  J. Elrod,et al.  Extracellular matrix, junctional integrity and matrix metalloproteinase interactions in endothelial permeability regulation * , 2002, Journal of anatomy.

[229]  C. Dinarello,et al.  Proinflammatory cytokines. , 2000, Chest.

[230]  R. Fridman,et al.  MT1-MMP shedding involves an ADAM and is independent of its localization in lipid rafts. , 2006, Biochemical and biophysical research communications.

[231]  R. Fridman,et al.  MMP-2 colocalizes with caveolae on the surface of endothelial cells. , 2001, Experimental cell research.

[232]  M. Hellwig,et al.  Soluble Human Interleukin–4 Receptor Is Produced by Activated T Cells under the Control of Metalloproteinases , 1999, International Archives of Allergy and Immunology.

[233]  R. Bast,et al.  Regulation of tumour necrosis factor-alpha processing by a metalloproteinase inhibitor. , 1994, Nature.

[234]  P. Galle,et al.  Cleavage of CD95 by matrix metalloproteinase-7 induces apoptosis resistance in tumour cells , 2004, Oncogene.

[235]  A. Elhabazi,et al.  Biological Activity of Soluble CD100. I. The Extracellular Region of CD100 Is Released from the Surface of T Lymphocytes by Regulated Proteolysis1 , 2001, The Journal of Immunology.

[236]  P. E. Van den Steen,et al.  Hemopexin domains as multifunctional liganding modules in matrix metalloproteinases and other proteins , 2007, Journal of leukocyte biology.

[237]  Z. Werb,et al.  Synergy between a plasminogen cascade and MMP-9 in autoimmune disease. , 2005, The Journal of clinical investigation.

[238]  I. Stamenkovic,et al.  Localization of matrix metalloproteinase 9 to the cell surface provides a mechanism for CD44-mediated tumor invasion. , 1999, Genes & development.

[239]  Yunbo Shi,et al.  Spatio‐temporal regulation and cleavage by matrix metalloproteinase stromelysin‐3 implicate a role for laminin receptor in intestinal remodeling during Xenopus laevis metamorphosis , 2005, Developmental dynamics : an official publication of the American Association of Anatomists.

[240]  P. Libby,et al.  Generation of biologically active IL-1 beta by matrix metalloproteinases: a novel caspase-1-independent pathway of IL-1 beta processing. , 1998, Journal of immunology.

[241]  K. Ley,et al.  Selectins in T-cell recruitment to non-lymphoid tissues and sites of inflammation , 2004, Nature Reviews Immunology.

[242]  E. Ziff,et al.  Membrane Localization of Membrane Type 5 Matrix Metalloproteinase by AMPA Receptor Binding Protein and Cleavage of Cadherins , 2006, The Journal of Neuroscience.

[243]  B. Fingleton,et al.  Matrix metalloproteinase-3-dependent generation of a macrophage chemoattractant in a model of herniated disc resorption. , 2000, The Journal of clinical investigation.

[244]  Z. Werb,et al.  How matrix metalloproteinases regulate cell behavior. , 2001, Annual review of cell and developmental biology.

[245]  E. Milgrom,et al.  Sequential Cleavage and Excision of a Segment of the Thyrotropin Receptor Ectodomain* , 1999, The Journal of Biological Chemistry.

[246]  J. Ochieng,et al.  Modulation of the biological functions of galectin-3 by matrix metalloproteinases. , 1998, Biochimica et biophysica acta.

[247]  M. Campiglio,et al.  The 67 kDa laminin receptor increases tumor aggressiveness by remodeling laminin-1. , 2005, Endocrine-related cancer.

[248]  Y. Okada,et al.  Cleavage of metastasis suppressor gene product KiSS-1 protein/metastin by matrix metalloproteinases , 2003, Oncogene.

[249]  M. Wewers IL-1beta: an endosomal exit. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[250]  R. Mayer,et al.  Activation of Human Leukocytes Reduces Surface P-Selectin Glycoprotein Ligand-1 (PSGL-1, CD162) and Adhesion to P-Selectin In Vitro1 , 2000, The Journal of Immunology.

[251]  M. Griese,et al.  Surfactant protein D in human lung diseases , 2006, European journal of clinical investigation.

[252]  K. Ley,et al.  L‐selectin: mechanisms and physiological significance of ectodomain cleavage , 2005, Journal of cellular and molecular medicine.

[253]  Dominic M. Walsh,et al.  Deciphering the Molecular Basis of Memory Failure in Alzheimer's Disease , 2004, Neuron.

[254]  Motoharu Seiki,et al.  The cell surface: the stage for matrix metalloproteinase regulation of migration. , 2002, Current opinion in cell biology.

[255]  A. Agarwal,et al.  PAR1 Is a Matrix Metalloprotease-1 Receptor that Promotes Invasion and Tumorigenesis of Breast Cancer Cells , 2005, Cell.

[256]  George Kollias,et al.  The function of tumour necrosis factor and receptors in models of multi-organ inflammation, rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease , 1999, Annals of the rheumatic diseases.

[257]  A. Mohsenin,et al.  PECAM‐1 shedding during apoptosis generates a membrane‐anchored truncated molecule with unique signaling characteristics , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[258]  T. Shofuda,et al.  Membrane‐type matrix metalloproteinase‐1 and ‐3 activity in primate smooth muscle cells , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[259]  H. Yamane,et al.  HEMOSTASIS , THROMBOSIS , AND VASCULAR BIOLOGY Inflammatory Cytokines and Vascular Endothelial Growth Factor Stimulate the Release of Soluble Tie Receptor From Human Endothelial Cells Via Metalloprotease Activation , 1999 .

[260]  S. Shapiro Immunology: Mobilizing the army , 2003, Nature.

[261]  R. Pope Apoptosis as a therapeutic tool in rheumatoid arthritis , 2002, Nature Reviews Immunology.

[262]  H. Kowarzyk Structure and Function. , 1910, Nature.

[263]  I. Stamenkovic,et al.  Matrix metalloproteinase-7-mediated cleavage of Fas ligand protects tumor cells from chemotherapeutic drug cytotoxicity. , 2001, Cancer research.

[264]  J. Gutkind,et al.  MT1-MMP Controls Tumor-induced Angiogenesis through the Release of Semaphorin 4D* , 2007, Journal of Biological Chemistry.

[265]  M. Tortorella,et al.  Inhibition of ADAM-TS4 and ADAM-TS5 Prevents Aggrecan Degradation in Osteoarthritic Cartilage* , 2002, The Journal of Biological Chemistry.

[266]  M. Cinelli,et al.  Matrix metalloproteinase 12-dependent cleavage of urokinase receptor in systemic sclerosis microvascular endothelial cells results in impaired angiogenesis. , 2004, Arthritis and rheumatism.

[267]  M. Bachem,et al.  Oxidized Low-Density Lipoproteins Stimulate Extracellular Matrix Metalloproteinase Inducer (EMMPRIN) Release by Coronary Smooth Muscle Cells , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[268]  J. Zwerina,et al.  Mechanisms of Disease: the link between RANKL and arthritic bone disease , 2005, Nature Clinical Practice Rheumatology.

[269]  G. Opdenakker,et al.  The molecular basis of leukocytosis. , 1998, Immunology today.

[270]  Y. Okada,et al.  Constitutive and Induced CD44 Shedding by ADAM-Like Proteases and Membrane-Type 1 Matrix Metalloproteinase , 2004, Cancer Research.

[271]  M. Piccart-Gebhart Adjuvant trastuzumab therapy for HER2-overexpressing breast cancer: what we know and what we still need to learn. , 2006, European journal of cancer.

[272]  A. Strongin,et al.  The Low Density Lipoprotein Receptor-related Protein LRP Is Regulated by Membrane Type-1 Matrix Metalloproteinase (MT1-MMP) Proteolysis in Malignant Cells* , 2004, Journal of Biological Chemistry.

[273]  Séverine Brulé,et al.  The shedding of syndecan-4 and syndecan-1 from HeLa cells and human primary macrophages is accelerated by SDF-1/CXCL12 and mediated by the matrix metalloproteinase-9. , 2006, Glycobiology.

[274]  M. Klagsbrun,et al.  Heparin-binding EGF-like growth factor. , 1997, Biochimica et biophysica acta.

[275]  D. Metcalfe,et al.  The biology of Kit in disease and the application of pharmacogenetics. , 2004, The Journal of allergy and clinical immunology.

[276]  J. Arribas,et al.  Protein ectodomain shedding. , 2002, Chemical reviews.

[277]  Z. Werb,et al.  The Serpin α1-Proteinase Inhibitor Is a Critical Substrate for Gelatinase B/MMP-9 In Vivo , 2000, Cell.

[278]  K. Frei,et al.  Occludin proteolysis and increased permeability in endothelial cells through tyrosine phosphatase inhibition. , 1999, Journal of cell science.

[279]  Stephen J. Weiss,et al.  Regulation of membrane-type matrix metalloproteinase 1 activity by dynamin-mediated endocytosis , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[280]  X. Puente,et al.  Protease degradomics: mass spectrometry discovery of protease substrates and the CLIP-CHIP, a dedicated DNA microarray of all human proteases and inhibitors , 2004, Biological chemistry.

[281]  A. Strongin,et al.  Processing of Integrin αv Subunit by Membrane Type 1 Matrix Metalloproteinase Stimulates Migration of Breast Carcinoma Cells on Vitronectin and Enhances Tyrosine Phosphorylation of Focal Adhesion Kinase* , 2002, The Journal of Biological Chemistry.

[282]  Hongtao Liu,et al.  The role of apoptosis in rheumatoid arthritis. , 2003, Current opinion in pharmacology.

[283]  Bo Liu,et al.  Stem cell factor and c-kit are expressed by and may affect vascular SMCs through an autocrine pathway. , 2004, The Journal of surgical research.

[284]  M. Kai,et al.  Heparin-Binding EGF-Like Growth Factor Is a Promising Target for Ovarian Cancer Therapy , 2004, Cancer Research.

[285]  C. Dijkstra,et al.  The FASEB Journal • FJ Express Full-Length Article Diapedesis of , 2022 .

[286]  Antal‐Szalmás,et al.  Evaluation of CD14 in host defence , 2000, European journal of clinical investigation.

[287]  L. Lum,et al.  Biochemical and Pharmacological Criteria Define Two Shedding Activities for TRANCE/OPGL That Are Distinct from the Tumor Necrosis Factor α Convertase* , 2001, The Journal of Biological Chemistry.

[288]  Y. Takada,et al.  ADAM12/Syndecan-4 Signaling Promotes β1Integrin-dependent Cell Spreading through Protein Kinase Cα and RhoA* , 2002, The Journal of Biological Chemistry.

[289]  G. Till,et al.  A major role for neutrophils in experimental bullous pemphigoid. , 1997, The Journal of clinical investigation.

[290]  H. Salih,et al.  Release of MICB molecules by tumor cells: mechanism and soluble MICB in sera of cancer patients. , 2006, Human immunology.

[291]  A. Shinagawa,et al.  Expression of the membrane-type 3 matrix metalloproteinase (MT3-MMP) in human brain tissues , 1998, Acta Neuropathologica.

[292]  Jin-Moo Lee,et al.  Matrix Metalloproteinase-9 Degrades Amyloid-β Fibrils in Vitro and Compact Plaques in Situ* , 2006, Journal of Biological Chemistry.

[293]  Michael J. Cullen,et al.  Matrix Metalloproteinase-9 (MMP-9) Is Synthesized in Neurons of the Human Hippocampus and Is Capable of Degrading the Amyloid-β Peptide (1–40) , 1996, The Journal of Neuroscience.

[294]  P. McGuire,et al.  Matrix metalloproteinases in early diabetic retinopathy and their role in alteration of the blood–retinal barrier , 2005, Laboratory Investigation.

[295]  J. Powell,et al.  Shear stress‐induced shedding of soluble intercellular adhesion molecule‐1 from saphenous vein endothelium , 2004, FEBS letters.

[296]  I. Stamenkovic,et al.  Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. , 2000, Genes & development.

[297]  E. Kojro,et al.  Ligand-induced Cleavage of the V2 Vasopressin Receptor by a Plasma Membrane Metalloproteinase (*) , 1995, The Journal of Biological Chemistry.

[298]  H. Schaller,et al.  Ectodomain shedding, translocation and synthesis of SorLA are stimulated by its ligand head activator. , 2000, Journal of cell science.

[299]  Pedro Romero,et al.  Matrix metalloproteinase 9 (MMP-9/gelatinase B) proteolytically cleaves ICAM-1 and participates in tumor cell resistance to natural killer cell-mediated cytotoxicity , 2002, Oncogene.

[300]  R. Kemler,et al.  Curbing the nuclear activities of beta-catenin. Control over Wnt target gene expression. , 2000, EMBO reports.

[301]  Clifford J. Woolf,et al.  Pain: Moving from Symptom Control toward Mechanism-Specific Pharmacologic Management , 2004, Annals of Internal Medicine.

[302]  J. Walker,et al.  Apoptosis a relevant therapeutic target in rheumatoid arthritis? , 2004, Rheumatology.

[303]  R. Black,et al.  A metalloprotease inhibitor blocks shedding of the 80-kD TNF receptor and TNF processing in T lymphocytes , 1995, The Journal of experimental medicine.

[304]  S. Bombardieri,et al.  Systemic sclerosis fibroblasts inhibit in vitro angiogenesis by MMP‐12‐dependent cleavage of the endothelial cell urokinase receptor , 2006, The Journal of pathology.

[305]  A. Strongin,et al.  Membrane type-1 matrix metalloproteinase (MT1-MMP) processing of pro-αv integrin regulates cross-talk between αvβ3 and α2β1 integrinsin breast carcinoma cells , 2003 .

[306]  A. Mantovani,et al.  Bacterial lipopolysaccharide causes rapid shedding, followed by inhibition of mRNA expression, of the IL-1 type II receptor, with concomitant up-regulation of the type I receptor and induction of incompletely spliced transcripts. , 1999, Journal of immunology.

[307]  P. Wallace,et al.  Endotoxin induces rapid metalloproteinase‐mediated shedding followed by up‐regulation of the monocyte hemoglobin scavenger receptor CD163 , 2002, Journal of leukocyte biology.

[308]  A. Rapraeger,et al.  Syndecans in tumor cell adhesion and signaling , 2004, Reproductive biology and endocrinology : RB&E.

[309]  J. Bonventre,et al.  Recent advances in the pathophysiology of ischemic acute renal failure. , 2003, Journal of the American Society of Nephrology : JASN.

[310]  Z. Werb,et al.  Gelatinase B–deficient Mice Are Resistant to Experimental Bullous Pemphigoid , 1998, The Journal of experimental medicine.

[311]  G. Bazzoni Endothelial tight junctions: permeable barriers of the vessel wall , 2005, Thrombosis and Haemostasis.

[312]  N. O. Solum,et al.  Release of soluble CD40 ligand after platelet activation: studies on the solubilization phase. , 2004, Thrombosis research.

[313]  M. Lambert,et al.  Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-α , 1997, Nature.

[314]  S. Pflugfelder,et al.  Advances in the diagnosis and management of keratoconjunctivitis sicca. , 1998, Current opinion in ophthalmology.

[315]  R. Nagle,et al.  Cleavage of β4 Integrin by Matrilysin , 1997 .

[316]  E. Raines,et al.  Emerging roles for ectodomain shedding in the regulation of inflammatory responses , 2006, Journal of leukocyte biology.

[317]  S. Shapiro,et al.  A critical role for neutrophil elastase in experimental bullous pemphigoid. , 2000, The Journal of clinical investigation.

[318]  D. Pinkel,et al.  The Stromal Proteinase MMP3/Stromelysin-1 Promotes Mammary Carcinogenesis , 1999, Cell.

[319]  R. Koehler,et al.  Dopamine Receptor Modulation of Hypoxic—Ischemic Neuronal Injury in Striatum of Newborn Piglets , 2007, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[320]  Takashi Ishikawa,et al.  Matrilysin (MMP-7) degrades VE-cadherin and accelerates accumulation of beta-catenin in the nucleus of human umbilical vein endothelial cells. , 2006, Oncology reports.

[321]  M. Tessier-Lavigne,et al.  Function of an axonal chemoattractant modulated by metalloprotease activity. , 2000, Science.

[322]  F. Rentsch Preretinal proliferation of glial cells after mechanical injury of the rabbit retina , 1973, Albrecht von Graefes Archiv für klinische und experimentelle Ophthalmologie.

[323]  D. Pei Matrix metalloproteinases target protease-activated receptors on the tumor cell surface. , 2005, Cancer cell.

[324]  L. Kaczmarek,et al.  Matrix metalloproteinases in the adult brain physiology: a link between c‐Fos, AP‐1 and remodeling of neuronal connections? , 2002, The EMBO journal.

[325]  B. Toole,et al.  Tumorigenic potential of extracellular matrix metalloproteinase inducer. , 2001, The American journal of pathology.

[326]  C. Masters,et al.  Gelatinase A possesses a β‐secretase‐like activity in cleaving the amyloid protein precursor of Alzheimer's disease , 1995 .

[327]  Luzhe Sun,et al.  Systemic administration of a soluble betaglycan suppresses tumor growth, angiogenesis, and matrix metalloproteinase‐9 expression in a human xenograft model of prostate cancer , 2005, The Prostate.

[328]  B. Fingleton,et al.  Matrilysin [MMP-7] expression selects for cells with reduced sensitivity to apoptosis. , 2001, Neoplasia.

[329]  Séverine Brulé,et al.  Regulated Shedding of Syndecan Ectodomains by Chemokines , 2006, TheScientificWorldJournal.

[330]  John Calvin Reed Mechanisms of apoptosis avoidance in cancer. , 1999, Current opinion in oncology.

[331]  J. Buxbaum,et al.  Evidence that tumor necrosis factor alpha converting enzyme is involved in regulated alpha-secretase cleavage of the Alzheimer amyloid protein precursor. , 1998, The Journal of biological chemistry.

[332]  A. Thathiah,et al.  MT1-MMP mediates MUC1 shedding independent of TACE/ADAM17. , 2004, The Biochemical journal.

[333]  D. Collen Ham-Wasserman lecture: role of the plasminogen system in fibrin-homeostasis and tissue remodeling. , 2001, Hematology. American Society of Hematology. Education Program.

[334]  Zhi Liu Immunopathology of bullous pemphigoid, an autoimmune and inflammatory skin blistering disease. , 2003, The Keio journal of medicine.

[335]  María Yáñez-Mó,et al.  Caveolae are a novel pathway for membrane-type 1 matrix metalloproteinase traffic in human endothelial cells. , 2003, Molecular biology of the cell.

[336]  K. Bloom,et al.  The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy. , 2003, The oncologist.

[337]  R. Timpl,et al.  Membrane-type matrix metalloproteinases 1 and 2 exhibit broad-spectrum proteolytic capacities comparable to many matrix metalloproteinases. , 1997, European journal of biochemistry.

[338]  I. Stamenkovic,et al.  CD44 anchors the assembly of matrilysin/MMP-7 with heparin-binding epidermal growth factor precursor and ErbB4 and regulates female reproductive organ remodeling. , 2002, Genes & development.

[339]  Constance E. Brinckerhoff,et al.  Matrix metalloproteinases: a tail of a frog that became a prince , 2002, Nature Reviews Molecular Cell Biology.

[340]  David A. Cheresh,et al.  Role of integrins in cell invasion and migration , 2002, Nature Reviews Cancer.

[341]  Tomoyuki Shirai,et al.  MMP-7 promotes prostate cancer-induced osteolysis via the solubilization of RANKL. , 2005, Cancer cell.

[342]  T. Davis,et al.  The Blood-Brain Barrier/Neurovascular Unit in Health and Disease , 2005, Pharmacological Reviews.

[343]  R. Kemler,et al.  Curbing the nuclear activities of β‐catenin , 2000 .

[344]  T. Schöneberg,et al.  The Fate of Desmosomal Proteins in Apoptotic Cells* , 2001, The Journal of Biological Chemistry.

[345]  K. Tanabe,et al.  The role of Fas ligand and transforming growth factor beta in tumor progression: molecular mechanisms of immune privilege via Fas-mediated apoptosis and potential targets for cancer therapy. , 2004, Cancer.

[346]  J W Smith,et al.  Substrate Hydrolysis by Matrix Metalloproteinase-9* , 2001, The Journal of Biological Chemistry.

[347]  A. Shimizu,et al.  A transmembrane chemokine, CXC chemokine ligand 16, expressed by lymph node fibroblastic reticular cells has the potential to regulate T cell migration and adhesion. , 2006, International immunology.

[348]  R. Béliveau,et al.  Ischemia injury alters endothelial cell properties of kidney cortex: stimulation of MMP-9. , 2005, Experimental cell research.

[349]  M. Schwartz,et al.  Matrix metalloproteinase inhibitors as prospective agents for the prevention and treatment of cardiovascular and neoplastic diseases. , 2006, Current topics in medicinal chemistry.

[350]  M. Rio From a unique cell to metastasis is a long way to go: clues to stromelysin-3 participation. , 2005, Biochimie.

[351]  A. Strongin,et al.  The Hemopexin-like C-terminal Domain of Membrane Type 1 Matrix Metalloproteinase Regulates Proteolysis of a Multifunctional Protein, gC1qR* , 2002, The Journal of Biological Chemistry.

[352]  S. Tsukita,et al.  Claudins in occluding junctions of humans and flies. , 2006, Trends in cell biology.

[353]  U. Yazdani,et al.  The semaphorins , 2006, Genome Biology.

[354]  Z. Hochberg,et al.  Shedding of growth hormone-binding protein is inhibited by hydroxamic acid-based protease inhibitors: proposed mechanism of activation of growth hormone-binding protein secretase. , 2001, The Journal of endocrinology.

[355]  J. Baselga,et al.  Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. , 2001, Cancer research.

[356]  M. Milla,et al.  The tumor necrosis factor-alpha converting enzyme (TACE): a unique metalloproteinase with highly defined substrate selectivity. , 2002, Biochemistry.

[357]  S. Bohlson,et al.  CD93 Is Rapidly Shed from the Surface of Human Myeloid Cells and the Soluble Form Is Detected in Human Plasma1 , 2005, The Journal of Immunology.

[358]  R. Wynn,et al.  Purification and cloning of aggrecanase-1: a member of the ADAMTS family of proteins. , 1999, Science.

[359]  G. Opdenakker,et al.  Gelatinase in the cerebrospinal fluid of patients with multiple sclerosis and other inflammatory neurological disorders , 1992, Journal of Neuroimmunology.

[360]  J. Sandy,et al.  ADAMTS4 (Aggrecanase-1) Activation on the Cell Surface Involves C-terminal Cleavage by Glycosylphosphatidyl Inositol-anchored Membrane Type 4-Matrix Metalloproteinase and Binding of the Activated Proteinase to Chondroitin Sulfate and Heparan Sulfate on Syndecan-1* , 2004, Journal of Biological Chemistry.

[361]  Gerhard Christofori,et al.  Cell adhesion and signalling by cadherins and Ig-CAMs in cancer , 2004, Nature Reviews Cancer.

[362]  B. H. Shah,et al.  Matrix metalloproteinases in reproductive endocrinology , 2004, Trends in Endocrinology & Metabolism.

[363]  P. Carmeliet,et al.  uPAR: a versatile signalling orchestrator , 2002, Nature Reviews Molecular Cell Biology.

[364]  S. Abraham,et al.  Caveolae--Not Just Craters in the Cellular Landscape , 2001, Science.

[365]  A. S. Appel,et al.  Acute Renal Failure , 1960, Advances in Experimental Medicine and Biology.

[366]  L. Lum,et al.  Evidence for a role of a tumor necrosis factor-alpha (TNF-alpha)-converting enzyme-like protease in shedding of TRANCE, a TNF family member involved in osteoclastogenesis and dendritic cell survival. , 1999, The Journal of biological chemistry.

[367]  D. Cho,et al.  Ligation of ICAM-1 molecules inhibits target cell-induced granule exocytosis of IL-12-activated natural killer cells. , 2000, Cellular immunology.

[368]  M. Ploug,et al.  Cell-surface acceleration of urokinase-catalyzed receptor cleavage. , 1997, European journal of biochemistry.

[369]  H. Mori,et al.  CD44 directs membrane‐type 1 matrix metalloproteinase to lamellipodia by associating with its hemopexin‐like domain , 2002, The EMBO journal.

[370]  E. Rovida,et al.  Transmodulation of Cell Surface Regulatory Molecules via Ectodomain Shedding , 2002, Biological chemistry.

[371]  L. Rassenti,et al.  The soluble CD40 ligand sCD154 in systemic lupus erythematosus. , 1999, The Journal of clinical investigation.

[372]  E. Sturrock,et al.  Modulation of juxtamembrane cleavage ("shedding") of angiotensin-converting enzyme by stalk glycosylation: evidence for an alternative shedding protease. , 1999, Biochemistry.

[373]  E. Sturrock,et al.  Phorbol ester-induced juxtamembrane cleavage of angiotensin-converting enzyme is not inhibited by a stalk containing intrachain disulfides. , 1998, Biochemistry.

[374]  J. Nadel,et al.  Cigarette smoke induces MUC5AC mucin overproduction via tumor necrosis factor-alpha-converting enzyme in human airway epithelial (NCI-H292) cells. , 2004, American journal of physiology. Lung cellular and molecular physiology.

[375]  D. Selkoe Alzheimer Disease: Mechanistic Understanding Predicts Novel Therapies , 2004, Annals of Internal Medicine.

[376]  G. Rosenberg,et al.  Blood–brain barrier disruption by stromelysin-1 facilitates neutrophil infiltration in neuroinflammation , 2006, Neurobiology of Disease.

[377]  S. Nagata,et al.  Downregulation of Fas ligand by shedding , 1998, Nature Medicine.

[378]  J. Massagué,et al.  Diverse Cell Surface Protein Ectodomains Are Shed by a System Sensitive to Metalloprotease Inhibitors (*) , 1996, The Journal of Biological Chemistry.

[379]  K. Bryniarski,et al.  Modulation of Macrophage Activity by Proteolytic Enzymes. Differential Regulation of IL-6 and Reactive Oxygen Intermediates (ROIs) Synthesis as a Possible Homeostatic Mechanism in the Control of Inflammation , 2003, Inflammation.

[380]  L. Lum,et al.  Evidence for a Role of a Tumor Necrosis Factor-α (TNF-α)-converting Enzyme-like Protease in Shedding of TRANCE, a TNF Family Member Involved in Osteoclastogenesis and Dendritic Cell Survival* , 1999, Journal of Biological Chemistry.

[381]  R. Nagle,et al.  Cleavage of beta 4 integrin by matrilysin. , 1997, Experimental cell research.

[382]  V. Magdolen,et al.  Molecular and Functional Interdependence of the Urokinase-Type Plasminogen Activator System with Integrins , 2003, Biological chemistry.

[383]  S. Chandler,et al.  Macrophage metalloelastase degrades matrix and myelin proteins and processes a tumour necrosis factor-alpha fusion protein. , 1996, Biochemical and biophysical research communications.

[384]  T. Petrucci,et al.  Axotomy of Sympathetic Neurons Activates the Metalloproteinase-2 Enzymatic Pathway , 2005, Journal of neuropathology and experimental neurology.

[385]  N. Delaleu,et al.  Interleukin-1 beta and interleukin-18: regulation and activity in local inflammation. , 2004, Periodontology 2000.

[386]  W. Jiang,et al.  Matrilysin mediates extracellular cleavage of E-cadherin from prostate cancer cells: a key mechanism in hepatocyte growth factor/scatter factor-induced cell-cell dissociation and in vitro invasion. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[387]  S. Théoleyre,et al.  The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling. , 2004, Cytokine & growth factor reviews.

[388]  J. Massagué,et al.  Betaglycan can act as a dual modulator of TGF-beta access to signaling receptors: mapping of ligand binding and GAG attachment sites , 1994, The Journal of cell biology.

[389]  J. Baselga,et al.  Cleavage of the HER2 ectodomain is a pervanadate-activable process that is inhibited by the tissue inhibitor of metalloproteases-1 in breast cancer cells. , 1999, Cancer research.

[390]  B. Fingleton,et al.  Identification of novel matrix metalloproteinase-7 (matrilysin) cleavage sites in murine and human Fas ligand. , 2002, Archives of biochemistry and biophysics.

[391]  B. H. Shah,et al.  A central role of EGF receptor transactivation in angiotensin II -induced cardiac hypertrophy. , 2003, Trends in pharmacological sciences.

[392]  F. Roufosse,et al.  SYSTEMIC SCLEROSIS (SCLERODERMA) , 2007, Acta clinica Belgica.

[393]  V. V. van Hinsbergh,et al.  Proteolysis of the urokinase-type plasminogen activator receptor by metalloproteinase-12: implication for angiogenesis in fibrin matrices. , 2001, Blood.

[394]  Motoharu Seiki,et al.  Membrane-type 1 matrix metalloproteinase: a key enzyme for tumor invasion. , 2003, Cancer letters.

[395]  N. Hooper,et al.  Angiotensin-converting enzyme secretase is inhibited by zinc metalloprotease inhibitors and requires its substrate to be inserted in a lipid bilayer. , 1997, The Biochemical journal.

[396]  P. Cameron,et al.  Identification of a monocyte specific pre-interleukin 1 beta convertase activity. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[397]  K. Preissner,et al.  The intact urokinase receptor is required for efficient vitronectin binding: receptor cleavage prevents ligand interaction , 1997, FEBS letters.

[398]  A. Reichenbach,et al.  P2Y receptor-mediated stimulation of Müller glial cell DNA synthesis: dependence on EGF and PDGF receptor transactivation. , 2003, Investigative ophthalmology & visual science.

[399]  J. Baselga,et al.  Metalloprotease-dependent Protransforming Growth Factor-α Ectodomain Shedding in the Absence of Tumor Necrosis Factor-α-converting Enzyme* , 2001, The Journal of Biological Chemistry.

[400]  J. Kobarg,et al.  A zinc metalloproteinase is responsible for the release of cd30 on human tumor cell lines , 1995, International journal of cancer.

[401]  T. Gudermann,et al.  Matrix Metalloproteinases 2 and 9 Mediate Epidermal Growth Factor Receptor Transactivation by Gonadotropin-releasing Hormone* , 2003, Journal of Biological Chemistry.

[402]  G. Opdenakker,et al.  Dystroglycan is selectively cleaved at the parenchymal basement membrane at sites of leukocyte extravasation in experimental autoimmune encephalomyelitis , 2006, The Journal of experimental medicine.

[403]  B. Imhof,et al.  Integrin‐dependent pathologies , 2003, The Journal of pathology.

[404]  P. Elwood,et al.  The conversion of the human membrane-associated folate binding protein (folate receptor) to the soluble folate binding protein by a membrane-associated metalloprotease. , 1991, The Journal of biological chemistry.

[405]  Jeffrey F. Thompson,et al.  Matrix Metalloproteinase-Mediated Disruption of Tight Junction Proteins in Cerebral Vessels is Reversed by Synthetic Matrix Metalloproteinase Inhibitor in Focal Ischemia in Rat , 2007, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[406]  F. Watt,et al.  Role of integrins in regulating epidermal adhesion, growth and differentiation , 2002, The EMBO journal.

[407]  E. Dı́az-Rodrı́guez,et al.  Cleavage of the TrkA neurotrophin receptor by multiple metalloproteases generates signalling‐competent truncated forms , 1999, The European journal of neuroscience.

[408]  E. Dejana,et al.  Endothelial cadherins and tumor angiogenesis. , 2006, Experimental cell research.

[409]  J. Marvaldi,et al.  Role of endoproteolytic processing in the adhesive and signaling functions of alphavbeta5 integrin. , 2000, The Journal of biological chemistry.

[410]  H. Mori,et al.  CD44 binding through the hemopexin-like domain is critical for its shedding by membrane-type 1 matrix metalloproteinase , 2005, Oncogene.

[411]  B. H. Shah,et al.  Neuropeptide-induced Transactivation of a Neuronal Epidermal Growth Factor Receptor Is Mediated by Metalloprotease-dependent Formation of Heparin-binding Epidermal Growth Factor* , 2004, Journal of Biological Chemistry.

[412]  H. Galla,et al.  Tyrosine phosphatase inhibition induces loss of blood–brain barrier integrity by matrix metalloproteinase-dependent and -independent pathways , 2004, Brain Research.

[413]  J. Strominger,et al.  Metalloprotease and serine protease are involved in cleavage of CD43, CD44, and CD16 from stimulated human granulocytes. Induction of cleavage of L-selectin via CD16. , 1994, Journal of immunology.

[414]  J. Kirkwood,et al.  Integrins and cancer. , 2007, Oncology.

[415]  David C. Lee,et al.  An essential role for ectodomain shedding in mammalian development. , 1998, Science.

[416]  Hiroshi Sato,et al.  Cleavage of apolipoprotein E by membrane-type matrix metalloproteinase-1 abrogates suppression of cell proliferation. , 2006, Journal of biochemistry.

[417]  K. Campbell,et al.  Dystroglycan: from biosynthesis to pathogenesis of human disease , 2006, Journal of Cell Science.

[418]  F. Blasi,et al.  Metalloproteases Cleave the Urokinase-Type Plasminogen Activator Receptor in the D1-D2 Linker Region and Expose Epitopes not Present in the intact Soluble Receptor , 2002, Thrombosis and Haemostasis.

[419]  G. Opdenakker,et al.  Functional roles and therapeutic targeting of gelatinase B and chemokines in multiple sclerosis , 2003, The Lancet Neurology.

[420]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[421]  J. Lissitzky,et al.  Biogenesis of α6β4 integrin in a human colonic adenocarcinoma cell line , 1999 .

[422]  A. Strongin,et al.  Cellular Membrane Type-1 Matrix Metalloproteinase (MT1-MMP) Cleaves C3b, an Essential Component of the Complement System* , 2004, Journal of Biological Chemistry.

[423]  L. Lum,et al.  Biochemical and pharmacological criteria define two shedding activities for TRANCE/OPGL that are distinct from the tumor necrosis factor alpha convertase. , 2001, The Journal of biological chemistry.

[424]  Rita Casadio,et al.  Transglutaminases: nature's biological glues. , 2002, The Biochemical journal.

[425]  K. Endresen,et al.  Platelet-derived LIGHT induces inflammatory responses in endothelial cells and monocytes. , 2006, Blood.

[426]  M. Pepper Role of the Matrix Metalloproteinase and Plasminogen Activator-Plasmin Systems in Angiogenesis , 2001, Arteriosclerosis, thrombosis, and vascular biology.